A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

984

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema (DME)

Interventions

DRUG: Ranibizumab
DRUG: EYE103

Sponsor

EyeBiotech Ltd.